Modality
Cell Therapy
MOA
IL-23i
Target
CD47
Pathway
Complement
NMOSDLGS
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
May 2022
→ Aug 2028
Phase 1Current
NCT06764708
615 pts·LGS
2022-05→2028-08·Active
615 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-083mo agoOrphan Drug· NMOSD
2028-08-252.4y awayPh2 Data· LGS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Active
Catalysts
Orphan Drug
2026-01-08 · 3mo ago
NMOSD
Ph2 Data
2028-08-25 · 2.4y away
LGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06764708 | Phase 1/2 | LGS | Active | 615 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |